摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(9Z,28Z)-heptatriaconta-9,28-dien-19-ol | 264627-92-1

中文名称
——
中文别名
——
英文名称
(9Z,28Z)-heptatriaconta-9,28-dien-19-ol
英文别名
——
(9Z,28Z)-heptatriaconta-9,28-dien-19-ol化学式
CAS
264627-92-1
化学式
C37H72O
mdl
——
分子量
532.978
InChiKey
HTTGRFFTCDSQNN-CLFAGFIQSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    16.5
  • 重原子数:
    38
  • 可旋转键数:
    32
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.89
  • 拓扑面积:
    20.2
  • 氢给体数:
    1
  • 氢受体数:
    1

反应信息

  • 作为反应物:
    描述:
    (9Z,28Z)-heptatriaconta-9,28-dien-19-ol 在 Dowex (Cl- form) 、 三乙胺 作用下, 以 二氯甲烷 为溶剂, 反应 24.0h, 生成 1-(dioleylmethyl)-4-methylpyridinium chloride
    参考文献:
    名称:
    Synthesis of Pyridinium Amphiphiles Used for Transfection and Some Characteristics of Amphiphile/DNA Complex Formation
    摘要:
    DOI:
    10.1002/(sici)1099-0690(200002)2000:4<665::aid-ejoc665>3.0.co;2-a
  • 作为产物:
    描述:
    1-溴-顺-9-十八碳烯 在 lithium aluminium tetrahydride 、 magnesium 作用下, 以 四氢呋喃 为溶剂, 反应 5.5h, 生成 (9Z,28Z)-heptatriaconta-9,28-dien-19-ol
    参考文献:
    名称:
    Lipids and compositions for the delivery of therapeutics
    摘要:
    本发明提供了有利用于体内向细胞传递治疗剂的脂质颗粒中的脂质。具体而言,该发明的公式(I)提供了具有以下结构XXXIII的脂质,其中:R1和R2分别独立地为每次出现的情况下,可以是选择性取代的C10-C30烷基,选择性取代的C10-C30烯基,选择性取代的C10-C30炔基,选择性取代的C10-C30酰基,或-连接-配体;R3为H,可以是选择性取代的C1-C10烷基,选择性取代的C2-C10烯基,选择性取代的C2-C10炔基,烷基杂环,烷基磷酸酯,烷基磷硫酸酯,烷基磷二硫酸酯,烷基磷酸酯,烷基胺,羟基烷基,ω-氨基烷基,ω-(取代)氨基烷基,ω-磷酰基烷基,ω-硫代磷酰基烷基,选择性取代的聚乙二醇(PEG,分子量100-40K),选择性取代的mPEG(分子量120-40K),杂环芳基,杂环,或连接-配体;E为C(O)O或OC(O)。
    公开号:
    US09186325B2
点击查看最新优质反应信息

文献信息

  • [EN] BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS<br/>[FR] LIPIDES BIODÉGRADABLES POUR L'ADMINISTRATION D'AGENTS ACTIFS
    申请人:ALNYLAM PHARMACEUTICALS INC
    公开号:WO2013086354A1
    公开(公告)日:2013-06-13
    The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
    本发明涉及一种阳离子脂质,其中在阳离子脂质的脂质部分(例如,疏水链)中具有一个或多个可生物降解的基团。这些阳离子脂质可以掺入脂质粒子中,用于递送一种活性剂,例如核酸。本发明还涉及包含中性脂质、能够减少聚集的脂质、本发明的阳离子脂质以及可选的甾醇的脂质粒子。脂质粒子还可以进一步包括治疗剂,例如核酸。
  • COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B
    申请人:Heyes James
    公开号:US20130123339A1
    公开(公告)日:2013-05-16
    The present invention provides compositions and methods for the delivery of interfering RNAs such as siRNAs that silence APOB expression in cells such as liver cells. In particular, the nucleic acid-lipid particles provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells such as liver cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of APOB at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.
    本发明提供了一种用于传递干扰RNA(如siRNA)的组合物和方法,用于在细胞中(如肝细胞)沉默APOB表达。具体来说,核酸-脂质颗粒能够有效地封装核酸,并有效地将封装的核酸传递给体内的细胞,如肝细胞。本发明的组合物非常有效,因此可以在相对较低的剂量下有效地降低APOB的表达。此外,与先前已知的技术相比,本发明的组合物和方法毒性较低,并且提供了更大的治疗指数。
  • BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS
    申请人:ALNYLAM PHARMACEUTICALS, INC.
    公开号:US20160009637A1
    公开(公告)日:2016-01-14
    The present invention relates to a cationic lipid having one or more biodegradable groups located in the mid- or distal section of a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
    本发明涉及一种阳离子脂质,其具有位于脂质基团(例如,疏水链)的中部或远端部位的一个或多个可生物降解的基团。这些阳离子脂质可以被纳入脂质颗粒中,用于传递活性剂,例如核酸。该发明还涉及包括中性脂质、能够减少聚集的脂质、本发明的阳离子脂质以及可选地固醇的脂质颗粒。脂质颗粒还可以进一步包含治疗剂,如核酸。
  • IONIZABLE CATIONIC LIPIDS
    申请人:Akagera Medicines, Inc.
    公开号:US20220162521A1
    公开(公告)日:2022-05-26
    The present disclosure provides compounds useful as ionizable cationic lipids. The ionizable cationic lipids are useful for preparing lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids were engineered with improved stability to oxidative degradation while in storage.
    本公开提供了可用作离子化阳离子脂质体的化合物。这些离子化阳离子脂质体可用于制备脂质纳米粒子,以将治疗性核酸传递到细胞中。改进了阳离子离子化脂质体的稳定性,以防止在储存过程中发生氧化降解。
  • NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS
    申请人:Manoharan Muthiah
    公开号:US20110311582A1
    公开(公告)日:2011-12-22
    The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention formula (I) provides lipids having the following structure XXXIII wherein: R 1 and R 2 are each independently for each occurrence optionally substituted C 10 -C 30 alkyl, optionally substituted C 10 -C 30 alkenyl, optionally substituted C 10 -C 30 alkynyl, optionally substituted C 10 -C 30 acyl, or -linker-ligand; R 3 is H, optionally substituted C 1 -C 10 alkyl, optionally substituted C 2 -C 10 alkenyl, optionally substituted C 2 -C 10 alkynyl, alky lhetro cycle, alkylphosphate, alkylphosphorothioate, alkylphosphorodithioate, alkylphosphonates, alkylamines, hydroxyalkyls, ω-aminoalkyls, ω-(substituted)aminoalkyls, ω-phosphoalkyls, ω-thiophosphoalkyls, optionally substituted polyethylene glycol (PEG, mw 100-40K), optionally substituted mPEG (mw 120-40K), heteroaryl, heterocycle, or linker-ligand; and E is C(O)O or OC(O).
    本发明提供了脂质,这些脂质在体内传递治疗剂到细胞的脂质颗粒中具有优势。特别是,本发明公式(I)提供了具有以下结构XXXIII的脂质,其中:R1和R2分别为每次出现的可选取代C10-C30烷基,可选取代C10-C30烯基,可选取代C10-C30炔基,可选取代C10-C30酰基,或-连接物-配基; R3为H,可选取代C1-C10烷基,可选取代C2-C10烯基,可选取代C2-C10炔基,烷基杂环,烷基磷酸盐,烷基磷酸硫酸盐,烷基磷酸二硫酸盐,烷基膦酸盐,烷基胺,羟基烷基,ω-氨基烷基,ω-(取代)氨基烷基,ω-磷酸基烷基,ω-硫代磷酸基烷基,可选取代聚乙二醇(PEG,mw 100-40K),可选取代mPEG(mw 120-40K),杂环芳基,杂环,或连接物配基; E为C(O)O或OC(O)。
查看更多